Kura Oncology (NASDAQ:KURA) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.97 and traded as low as $5.85. Kura Oncology shares last traded at $6.16, with a volume of 1,985,284 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have commented on KURA shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Mizuho reduced their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, May 19th. Barclays lowered their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. JMP Securities reissued a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Wednesday, June 4th. Finally, Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.50.

Kura Oncology Price Performance

The firm has a 50 day moving average of $6.07 and a two-hundred day moving average of $6.95. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.02. The company has a market cap of $549.29 million, a PE ratio of -3.02 and a beta of 0.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. Research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. State of Wyoming bought a new stake in shares of Kura Oncology during the first quarter valued at approximately $48,000. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in Kura Oncology in the first quarter worth approximately $66,000. Flower City Capital bought a new position in Kura Oncology in the first quarter worth approximately $79,000. Finally, Magnetar Financial LLC bought a new position in Kura Oncology in the first quarter worth approximately $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.